Grünenthal has successfully completed a Phase I trial for its proprietary nociceptin receptor (NOP) agonist, demonstrating safety and tolerability in 113 healthy volunteers. The company plans to advance the novel pain therapy into a Phase II trial later this year, with results expected in the second half of 2027.
The treatment landscape for multiple myeloma is evolving rapidly with T-cell engaging therapies like bispecific antibodies and CAR T-cell treatments shifting care toward a chronic condition with potential treatment breaks. This evolution is creating new side effect management challenges and complicating clinical trial design as sponsors grapple with selecting comparator arms and adapting to a rapidly shifting standard of care.
Research found women undergoing breast reconstruction after mastectomy have goals extending beyond physical restoration. Newer nerve-preserving techniques aim to restore chest and nipple sensation but are still being studied.
Post-mastectomy pain syndrome affects 10-50% of women after breast removal surgery, causing chronic pain that can last years. The condition lacks consistent diagnosis, standardized screening, and FDA-approved treatments, leaving many patients struggling to find relief. Recent research calls for increased focus on this undertreated complication of breast cancer survival success.
Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.
NRx Pharmaceuticals completed an in-person FDA Type C meeting regarding NRX-100, a preservative-free ketamine formulation for suicidal depression. The company received guidance on a path to file a New Drug Application based on existing trial data and Real World Evidence from over 65,000 patients.
New research from Michigan State University reveals that differences in hormone-regulated monocytes explain why women experience longer-lasting chronic pain than men, with males producing more IL-10 to shut down pain signals.
NRx Pharmaceuticals completed a Type C meeting with the FDA, receiving guidance to file a New Drug Application for NRX-100 based on existing trial data and real-world evidence from over 65,000 patients, with submission planned for Q2 2026.
NRx Pharmaceuticals completed a Type C meeting with FDA leadership and received oral guidance supporting a New Drug Application for NRX-100 (preservative-free ketamine) based on existing trial data and Real World Evidence from over 65,000 patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07611799 |
Understanding Chronic Pain in NHS Grampian |
COMPLETED | |
| NCT07608952 |
The Women Veteran's Health Mission |
NOT_YET_RECRUITING | NA |
| NCT07607899 |
Virtual Reality for Pain and Well-Being in Older Adults |
NOT_YET_RECRUITING | NA |
| NCT07602595 |
The BRIDGE Pain Study |
RECRUITING | |
| NCT07600892 |
Pain-at-Work Toolkit (Definitive Trial) |
NOT_YET_RECRUITING | NA |
| NCT07583368 |
Chronic Pain, Emotions and Professional Football |
COMPLETED | |
| NCT07572591 |
Ultrasound for Peripheral Nerve Modulation |
NOT_YET_RECRUITING | NA |
| NCT07562412 |
Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain |
NOT_YET_RECRUITING | NA |
| NCT07561411 |
Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy |
NOT_YET_RECRUITING | NA |
| NCT07555314 |
Outpatient Midline Catheter in Patients Receiveing Lidocaine Infusion Series. |
RECRUITING |
